Evidence map›Paper›PMID 40105114›Full record

ArticleThe FEBS journal2025

The N6-methyladenosine reader IGF2BP3 promotes bladder cancer progression through enhancing HSP90AB1 expression.

Xiaoqing Chen, Wenli Diao, Xinyue Guo, Wenmin Cao, Yang Yang, Tianlei Xie, Wei Chen, Lin Yang, Qing Zhang, Meng Ding and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The FEBS journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Alantolactone curbs the malignant progression of bladder cancer partly via the HSP90AB1/LRP5/β-catenin axis.Mammalian genome : official journal of the International Mammalian Genome Society · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xiaoqing ChenDepartment of Urology, Nanjing Drum Tower Hospital, Clinical College of Nanjing University of Chinese Medicine, China.
Wenli DiaoDepartment of Urology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Institute of Urology, Nanjing University, China.
Xinyue GuoDepartment of Urology, Nanjing Drum Tower Hospital, Clinical College of Nanjing University of Chinese Medicine, China.
Wenmin CaoDepartment of Urology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Institute of Urology, Nanjing University, China.
Yang YangDepartment of Urology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Institute of Urology, Nanjing University, China.
Tianlei XieDepartment of Urology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Institute of Urology, Nanjing University, China.
Wei ChenDepartment of Urology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Institute of Urology, Nanjing University, China.
Lin YangDepartment of Urology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Institute of Urology, Nanjing University, China.
Qing ZhangDepartment of Urology, Nanjing Drum Tower Hospital, Clinical College of Nanjing University of Chinese Medicine, China.ORCID 0000-0003-2680-3111
Meng DingDepartment of Urology, Nanjing Drum Tower Hospital, Clinical College of Nanjing University of Chinese Medicine, China.ORCID 0000-0003-4042-2526
Hongqian GuoDepartment of Urology, Nanjing Drum Tower Hospital, Clinical College of Nanjing University of Chinese Medicine, China.ORCID 0000-0002-3121-5157

Funding

Nanjing Medical Science and technology development Foundation ZKX22024National Natural Science Foundation of China 81902571National Natural Science Foundation of China 81972388National Natural Science Foundation of China 82173160Natural Science Foundation of Jiangsu Province BK20190123
6 · The paper itself

Abstract

N

Indexed as

AdenosineGene Expression Regulation, NeoplasticHSP90 Heat-Shock ProteinsRNA-Binding ProteinsUrinary Bladder NeoplasmsAnimalsCell Line, TumorCell ProliferationDisease ProgressionFemaleHumansMaleMiceMice, Inbred BALB CMice, NudePhosphatidylinositol 3-KinasesAdenosineHSP90 Heat-Shock ProteinsIGF2BP3 protein, humanN-methyladenosinePhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRNA-Binding Proteinsbladder cancerHSP90AB1IGF2BP3m6API3K/AKT signaling

Identifiers

PMID40105114
PMCPMC12220844

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.